Cite
HARVARD Citation
Behrens, F. et al. (2015). MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Annals of the rheumatic diseases. 74 (6), pp. 1058-1064. [Online].